Medtronic Projects ICD Recovery In 2007, Double-Digit Growth Potential
This article was originally published in The Gray Sheet
Executive Summary
Medtronic remains confident that the worldwide implantable cardioverter defibrillator market will achieve low double-digit growth over the next five years despite current headwinds facing the sector
You may also be interested in...
J&J Gains Next-Gen CoStar Stent Through $1.4 Bil. Conor Purchase
Johnson & Johnson hopes that its $1.4 bil. purchase of next-generation drug-eluting stent developer Conor Medsystems will help it retain top-tier market share as a flurry of new competitors joins the market
J&J Gains Next-Gen CoStar Stent Through $1.4 Bil. Conor Purchase
Johnson & Johnson hopes that its $1.4 bil. purchase of next-generation drug-eluting stent developer Conor Medsystems will help it retain top-tier market share as a flurry of new competitors joins the market
St. Jude, Boston Scientific ICD Sales Growth Flat-Lines In Q3 – Rebound In ’07?
St. Jude Medical is more than halfway through a planned 500-rep expansion of its U.S. implantable cardioverter defibrillator sales force as part of its broader effort to reignite ICD sales growth